carubicin and Kidney-Neoplasms

carubicin has been researched along with Kidney-Neoplasms* in 2 studies

Trials

1 trial(s) available for carubicin and Kidney-Neoplasms

ArticleYear
[Experience with using carminomycin in oncological clinical practice].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1992, Volume: 37, Issue:3

    Carminomycin is an original antitumor antibiotic from the anthracycline group isolated at the Institute of New Antibiotics (USSR) in 1973. Pharmacological investigation of carminomycin revealed its satisfactory absorption from the gastrointestinal tract which proved to be a distinguishing property of the antibiotic as compared to other anthracyclines such as adriamycin and rubomycin. The clinical trials of carminomycin showed that it was mainly active against soft tissue sarcoma and breast cancer, lymphosarcoma, neuroblastoma, Wilms' tumor and Ewing's sarcoma in children, as well as acute leukemia. Various regimens for the antibiotic administration were applied: short-term, single and long-term. Suppression of hemopoiesis was considered as a limiting toxic effect. By the data available carminomycin had lower cardiotoxicity as compared with rubomycin and adriamycin. Development of oral carminomycin is believed promising.

    Topics: Adult; Breast Neoplasms; Carubicin; Child; Female; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Neoplasms; Sarcoma; Soft Tissue Neoplasms; Uterine Neoplasms; Wilms Tumor

1992

Other Studies

1 other study(ies) available for carubicin and Kidney-Neoplasms

ArticleYear
Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells.
    Cancer research, 2011, Jan-01, Volume: 71, Issue:1

    Clear cell renal cell carcinoma (CCRCC) evolves due to mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene. Although the loss of VHL enables survival and proliferation of CCRCC cells, it is also expected to introduce vulnerabilities that may be exploited for therapeutics discovery. To this end, we developed a high-throughput screen to identify small molecules derived from plants, microorganisms, and marine organisms to which CCRCC cells are sensitive. Screening over 8,000 compounds using this approach, we report here the identification of the microbially derived compound carminomycin I (CA) as an effective inhibitor of VHL-defective (VHL(-/-)) CCRCC cell proliferation. CA also induced apoptosis in CCRCC cells by a mechanism independent of p53 or hypoxia-inducible factor 2. We found that P-glycoprotein (P-gp) sequestered CA within the Golgi complex. Interestingly, Golgi sequestration was critical for the antiproliferative effects of CA and P-gp inhibitors abrogated this activity. Furthermore, CA induced cleavage of the Golgi protein p115 and the translocation of its C-terminal fragment to the nucleus. Finally, examination of the activity of the VHL-interacting Golgi protein, endoplasmic reticulum-Golgi intermediate compartment, ERGIC-53 showed that VHL could mediate protection from CA in CCRCC cells. Our natural product-based screening approach has revealed the P-gp-mediated localization of anticancer compounds within the Golgi in CCRCC cells as a potential strategy of targeting VHL-deficient CCRCC cells.

    Topics: Antibiotics, Antineoplastic; Apoptosis; Base Sequence; Blotting, Western; Carcinoma, Renal Cell; Carubicin; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Golgi Apparatus; Humans; Immunohistochemistry; Kidney Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference

2011